Do β-lactam-β-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis?
- 1 February 1995
- journal article
- other
- Published by Elsevier in Tubercle and Lung Disease
- Vol. 76 (1), 90-92
- https://doi.org/10.1016/0962-8479(95)90588-x
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Treatment of Multidrug-Resistant TuberculosisNew England Journal of Medicine, 1993
- Adverse Neurological Reactions in Patients with Multidrug-Resistant Pulmonary Tuberculosis After Coadministration of Cycloserine and OfloxacinClinical Infectious Diseases, 1993
- The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosisTubercle and Lung Disease, 1992
- A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicinTubercle and Lung Disease, 1992
- Amoxicillin-Clavulanic Acid for Treating Drug-Resistant Mycobacterium tuberculosisChest, 1991
- In-vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium kansasii to amoxycillin and ticarcillin in combination with clavulanic acidJournal of Antimicrobial Chemotherapy, 1988
- Comparison of four β-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosisJournal of Antimicrobial Chemotherapy, 1987
- In vitro susceptibility ofMycobacterium tuberculosis,Mycobacterium fortuitum andMycobacterium chelonei to augmentinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1986
- In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 1983
- The Nature of Mycobacterial Penicillinase1American Review of Respiratory Disease, 1965